A total of 378 novel drugs and 27 biosimilars approved by the US Food and Drug
Administration (FDA) between 2010 and 2019 were evaluated according to approval …

The case for a renewed focus on Nature in drug discovery is reviewed; not in terms of
natural product screening, but how and why biomimetic molecules, especially those …

Abstract Forty-eight (48) drug products (DPs) containing amorphous solid dispersions
(ASDs) have been approved by the US Food and Drug Administration in the 12-year period …

For oral drugs, medicinal chemists aim to design compounds with high oral bioavailability, of
which permeability is a key determinant. Taking advantage of> 2000 compounds tested in …

Drug design is central to the discovery of a new medicine, as the drug molecule embodies
the therapeutic hypothesis of a drug discovery program and encodes the properties …

Recurring coronavirus outbreaks, such as the current COVID-19 pandemic, establish a
necessity to develop direct-acting antivirals that can be readily administered and are active …

Developability molecule assessment is a key interfacial capability across the
biopharmaceutical industry, screening and staging molecules discovered by medicinal …

Highlights•Orally delivered drug products gradually continue to exceed the Rule-of-five on
Molecular Weight and clogP.•New predictive descriptors and tools, advanced chemistry and …

Advancement in biotechnology provided a notable expansion of peptide and protein
therapeutics, used as antigens, vaccines, hormones. It has a prodigious potential to treat a …

Physicochemical descriptors commonly used to define “drug-likeness” and ligand efficiency
measures are assessed for their ability to differentiate marketed drugs from compounds …